Spondyloarthritis & psoriatic arthritis
Psoriatic arthritis risk in psoriasis patients receiving anti-IL-23 vs anti-IL-17: comparison of drug classes and individual agents
Main finding · PsAResult — go to the resultHazard ratio 0.475 95% CI 0.382–0.590Authors' conclusion
PsO patients treated with IL23i had a lower subsequent PsA risk compared with those treated with IL17i.
Study context
- Population
- Adult psoriasis (PsO) patients without history of psoriatic arthritis (PsA) or previous anti-TNF-α or anti-IL-12/23 use, TriNetX databasematched 1:1
- Participants
- 5,490 patients
- Exposure
- IL-23 inhibitors vs IL-17 inhibitors in psoriasis
- Outcome
- PsA risk
Methodological detailspropensity-score matched 1:1, Cox regression, TriNetX database
- Propensity-score matched 1:1
- Cox regression
- TriNetX database
Main finding
PsA
Hazard ratio
0.475
95% CI 0.382–0.590
IL23ivs IL17i
HR 0.475 (95% CI 0.382–0.590)
As reported in the abstract
Observational data: associations, not effects.
Further findings
Cumulative incidence of PsA · 5 years
P < 0.001
| Outcome | HR (CI) | |
|---|---|---|
| PsA risk, individual drug comparisonsGuselkumabvs secukinumab | 0.480 (0.358–0.645) | |
| PsA risk, individual drug comparisonsGuselkumabvs ixekizumab | 0.698 (0.509–0.956) | |
| PsA risk, individual drug comparisonsRisankizumabvs secukinumab | 0.433 (0.306–0.612) | |
| PsA risk, individual drug comparisonsRisankizumabvs ixekizumab | 0.504 (0.347–0.732) | |
| PsA risk, individual drug comparisonsTildrakizumabvs secukinumab | 0.339 (0.131–0.875) | |
| PsA risk, individual drug comparisonsTildrakizumabvs ixekizumab | 0.451 (0.171–1.191) | |
| 0.10.31310Hazard ratio (log scale) |
PsA risk, subgroups (age, sex, race, PsO subtypes, obesity, elevated inflammatory markers)
- This reduced risk persisted across various subgroups
Original publication
Psoriatic arthritis risk in psoriasis patients receiving anti-IL-23 vs anti-IL-17: comparison of drug classes and individual agents. Rheumatology (Oxford). Published 17 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →